- Home
- RIGL vs ACRE Comparison
RIGL vs ACRE Comparison
Compare RIGL & ACRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RIGL | ACRE |
|---|---|---|
| Founded | 1996 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 537.6M | 254.1M |
| IPO Year | 2000 | 2012 |
Fundamental Metrics
Financial Performance| Metric | RIGL | ACRE |
|---|---|---|
| Price | $40.96 | $5.23 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 5 |
| Target Price | ★ $43.20 | $5.08 |
| AVG Volume (30 Days) | ★ 593.7K | 400.1K |
| Earning Date | 11-04-2025 | 11-07-2025 |
| Dividend Yield | N/A | ★ 11.52% |
| EPS Growth | ★ 2698.26 | N/A |
| EPS | ★ 6.20 | N/A |
| Revenue | ★ $282,076,000.00 | $87,777,000.00 |
| Revenue This Year | $65.53 | N/A |
| Revenue Next Year | $0.22 | N/A |
| P/E Ratio | $6.58 | ★ N/A |
| Revenue Growth | 79.13 | ★ 122.65 |
| 52 Week Low | $14.63 | $3.35 |
| 52 Week High | $52.24 | $7.27 |
Technical Indicators
Market Signals| Indicator | RIGL | ACRE |
|---|---|---|
| Relative Strength Index (RSI) | 47.40 | 60.64 |
| Support Level | $39.60 | $5.02 |
| Resistance Level | $43.58 | $5.27 |
| Average True Range (ATR) | 3.20 | 0.13 |
| MACD | -1.27 | -0.01 |
| Stochastic Oscillator | 11.83 | 70.59 |
Price Performance
Historical ComparisonAbout RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About ACRE Ares Commercial Real Estate Corporation
Ares Commercial Real Estate Corp is a specialty finance company and a Real Estate Investment Trust providing commercial real estate loans and related investments. It operates in one segment namely originating and managing a diversified portfolio of CRE debt-related investments. The group recognizes its revenues through the interest income it receives from loans.